About Coiled Therapeutics
Clinical stage precision oncology advancing first-in-class therapeutics for patients with high-risk cancers
Born from Urgency: A New Hope
At Coiled, we're building a new paradigm for precision medicine. Our journey began with the conviction that the next wave of therapeutic breakthroughs lies in precisely targeting historically intractable proteins, particularly coiled-coil and other structurally complex oncogenic targets.
Our story is one of relentless innovation and a deep belief in the power of combining advanced computational chemistry with rigorous structural biology. Today, Coiled stands at the forefront of a new era, fuelled by a commitment to patients. We believe that by systematically targeting cancer's core vulnerabilities, we can deliver truly transformative, precision therapeutics for those who need them most.
Spun out from A2A Pharmaceuticals, Inc. in 2025, Coiled is a focused, clinical-stage oncology company advancing promising new therapies for cancer.
Admission to AIM
Coiled Therapeutics plc was admitted to trading on AIM in March 2026 following the completion of the exclusive worldwide licence of AO-252 from Coiled Therapeutics, Inc., a spin out of A2A Pharma Pharmaceuticals Inc., and an associated £8.5 million fundraising. The Company's ordinary shares trade on AIM under the ticker COIL.
Admission to OTCQB Venture Market
In May 2026, Coiled Therapeutics plc's ordinary shares were admitted to cross-trading on the OTCQB Venture Market in the United States, operated by OTC Markets Group Inc., under the ticker COTXF. The OTCQB admission broadens access for U.S. investors, complementing the Company's primary listing on AIM and providing a transparent venue for trading by U.S. shareholders alongside the London market.
Live quotes, trade data and Company disclosures for the OTCQB cross-trading are available on the OTC Markets COTXF profile page.